Fatigue in neurological disorders

Lancet

Volumn 363, Issue 9413, 2004, Pages 978-988

  Chaudhuri, Abhijit ^a   Behan, Peter O ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINOPYRIDINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; GABAPENTIN; IMMUNOGLOBULIN; MELANOCORTIN 1 RECEPTOR; METHYLPHENIDATE; NEUROLEPTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; PEMOLINE; PYRIDOSTIGMINE; RECEPTOR BLOCKING AGENT; SUBSTANCE P ANTAGONIST; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID; VASOPRESSIN ANTAGONIST;

ANXIETY DISORDER; AUTONOMIC NEUROPATHY; BASAL GANGLION; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COGNITION; DISEASE EXACERBATION; DRUG EFFICACY; FATIGUE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIMBIC SYSTEM; MENTAL PERFORMANCE; METABOLIC DISORDER; MULTIPLE SCLEROSIS; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE FORCE; NEUROLOGIC DISEASE; NEUROMUSCULAR JUNCTION DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PERCEPTION; PERIPHERAL NEUROPATHY; PHYSICAL STRESS; POSTPOLIOMYELITIS SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; THALAMUS;

EID: 1642333956     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15794-2     Document Type: Review

References (94)

1. Adams R.D., Victor M., Ropper A.H. Fatigue, asthenia, anxiety and depressive reactions. Adams R.D., Victor M., Ropper A.H. Principles of neurology. 6th edn:1997;497-507 McGraw-Hill, New York.
2. Sharma O.P. Fatigue and sarcoidosis. Eur Resp J. 13:1999;713-714.
3. Branas P., Jordan R., Fry-Smith A., Burls A., Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 4:2000;1-61.
4. Bruno R.L. Paralytic versus "non-paralytic polio": a distinction without a difference? Am J Phys Med Rehabil. 79:1999;4-12.
5. Birk T.J. Poliomyelitis and post-polio syndrome: exercise capacity and adaptation: current research, future directions, and widespread applicability. Med Sci Sports Exerc. 25:1993;466-472.
6. Staub F., Bogousslavsky J. Fatigue after stroke: a major but neglected issue. Cerebrovascular Dis. 12:2001;75-81.
7. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 26:1989;155-156.
8. Kandel E.R., Schwartz J.H., Jessell T.M. The nervous system. Kandel E.R., Schwartz J.H., Jessell T.M. Essentials of neural science and behavior. 1995;71-88 Appleton and Lange, Connecticut.
9. Taivassalo T., Abbott A., Wyrick P., Haller R.G. Venous oxygen levels during aerobic forearm exercise: an index of impaired oxidative metabolism in mitochondrial myopathy. Ann Neurol. 51:2002;38-44.
10. Dalsgaard M.K., Nybo L., Cai Y., Secher N.H. Cerebral metabolism is influenced by muscle ischaemia during exercise in humans. Exp Physiol. 88:2003;297-302.
11. Latash M., Kalugina E., Nicholas J., et al. Myogenic and central neurogenic factors in fatigue in MS. Mult Scler. 1:1996;236-241.
12. Bruno R.L., Zimmerman J.R. Word finding difficulty as a post-polio sequelae. Am J Phys Med Rehabil. 79:2000;343-348.
13. Chaudhuri A., Behan P.O. Neurological dysfunction in chronic fatigue syndrome. J Chron Fatigue Syndr. 6:2000;51-68.
14. Fukuda K., Strauss S.E., Hickie I., et al. The chronic fatigue syndrome: a comprehensive approach to case definition and study. Ann Intern Med. 121:1994;953-959.
15. Chaudhuri A., Behan W.M.H., Behan P.O. Chronic fatigue syndrome. Proc R Coll Physicians Edinb. 28:1998;150-163.
16. Bagert B., Camplair P., Bourdette D. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs. 16:2002;445-455.
17. Krupp L.B., Elkins L.E. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology. 55:2000;934-939.
18. Bruno R.L., Galaski T., DeLuca J. The neuropsychology of post-polio fatigue. Arch Phys Med Rehabil. 74:1993;1061-1065.
19. van Zandvoort M.J., Kappelle L.J., Algra A., De Haan E.H. Decreased capacity for mental effort after single supratentorial lacunar infarct may affect performance in everyday life. J Neurol Neurosurg Psychiatry. 65:1998;697-702.
20. van Zandvoort M., de Haan E., van Gijn J., Kappelle L.J. Cognitive functioning in patients with a small infarct in the brain stem. J Int Neuropsychol Soc. 9:2003;490-494.
21. Isella V., Melzi P., Grimaldi M., et al. Clinical, neuropsychological and morphometric correlates of apathy in Parkinson's disease. Mov Disord. 17:2002;366-371.
22. DeLuca J., Johnson S.K., Ellis S.P., Natelson B.H. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry. 62:1997;151-155.
23. Tiersky L.A., DeLuca J., Hill N., et al. Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome. Appl Neuropsychol. 8:2001;41-50.
24. Stewart J.M., Gewitz M.H., Weldon A., et al. Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics. 103:1999;116-121.
25. Bruno R.L., Fick N.M., Crenage S.J. Nocturnal generalized myoclonus as a post-polio sequelae. Arch Phys Med Rehabil. 76:1995;594.
26. Glader E.L., Stegmayr B., Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke. 33:2002;1327-1333.
27. Chaudhuri A., Behan P.O. Fatigue and basal ganglia. J Neurol Sci. 179:2000;34-42.
28. Nauta WJH. The relationship of basal ganglia to the limbic system. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology, vol 49. Amsterdam: Elsevier Science, 1986: 19-32.
29. Alegret M., Valldeoriola F., Tolosa E., et al. Cognitive effects of unilateral posteroventral pallidotomy: a 4 year follow-up study. Mov Disord. 18:2003;323-328.
30. Ghika J., Ghika-Schmid F., Frankhauser H., et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects - report of four cases and review of literature. J Neurosurg. 91:1999;313-321.
31. Denny-Brown D. The basal ganglia and their relation to disorders of movement. 1962;Oxford University Press, Oxford.
32. Bruno R.L., Crenage S.J., Fick N.M. Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology? Am J Med. 105:1998;66S-73S.
33. Bradley L.A., Alarcon G.S. Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? Arthritis Rheum. 60:1999;471-473.
34. Barron J.L., Noakes T.D., Levy W., Smith C. Hypothalamic dysfunction in overtrained athletes. J Clin Endocrinol Metab. 60:1985;803-806.
35. Scammell T.E. The neurobiology, diagnosis and treatment of narcolepsy. Ann Neurol. 53:2003;154-166.
36. Steinman L. Autoimmune disease. Sci Am. 269:1993;106-114.
37. Harbuz M.S., Rees R.G., Ecland D., et al. Paradoxical responses of hypothalamic CRF mRNA and CRF-41 peptide and adenohypophyseal POMC mRNA during chronic inflammatory stress. Endocrinology. 130:1992;1394-1400.
38. Scott L.V., Dinan T.G. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Funct Neurol. 14:1999;3-11.
39. Yehuda R. Current status of cortisol findings in post-traumatic stress disorder. Psychiatr Clin North Am. 25:2002;341-368.
40. McEwen B.S. Protective and damaging effects of stress mediators. N Engl J Med. 338:1998;171-179.
41. Bruno R.L., Sapolsky R., Zimmerman J.R., Fick N.M. The pathophysiology of a central cause of post-polio fatigue. Ann N Y Acad Sci. 753:1995;257-275.
42. Whiting P., Bagnall A.M., Sowden A.J., Cornell J.E., Mulrow C.D. Intervention for the treatment and management of chronic fatigue syndrome. JAMA. 284:2001;1360-1368.
43. Dinsmore S., Dambrosia J., Dalakas M.C. A double blind, placebo-controlled trial of high dose prednisone for the treatment of post-poliomyelitis syndrome. Ann N Y Acad Sci. 753:1995;303-313.
44. Krupp L.B., Alvarez L.A., LaRocca N.G., Scheinberg L.C. Fatigue in multiple sclerosis. Arch Neurol. 45:1988;435-437.
45. Murray T.J. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 12:1985;251-254.
46. Freal J.E., Kraft G.H., Coryell J.K. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 65:1984;135-138.
47. Giesser B. Multiple sclerosis: current concepts in management. Drugs. 29:1985;88-95.
48. Giovannoni G., Thomson A.J., Miller D.H., Thompson E.J. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology. 57:2001;676-681.
49. Sheean G.L., Murray N.M.F., Rothwell J.C., Miller D.H., Thompson A.J. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain. 120:1997;299-315.
50. Leocani L., Colombo B., Magnani G., et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement: EEG evidence. NeuroImage. 13:2001;1186-1192.
51. Sandroni P., Walker C., Starr A. Fatigue in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol. 49:1992;517-524.
52. Bruno R.L., Crenage S.J., Zimmerman J.R., Fick N.M. Elevated plasma prolactin and EEG slow power in post-polio fatigue: implications for a dopamine deficiency underlying chronic fatigue syndrome. J Chron Fatigue Syndr. 4:1998;61-76.
53. Friedman J.H., Friedman H. Fatigue in Parkinson's disease. Neurology. 43:1993;2016-2018.
54. Hitten J.J., van Hoogland G., van der Velde E.A., et al. Diurnal effects of motor activity and fatigue in Parkinson's disease. J Neurol Neurosurg Psychiatry. 56:1993;874-877.
55. Comi G., Leocani L., Rossi P., Colombo B. Pathophysiology and treatment of fatigue in multiple sclerosis. J Neurol. 248:2001;174-179.
56. 18F-flurodeoxyglucose positron emission tomographic study. Neurology. 48:1997;1566-1571.
57. Fillipi M., Bozzali M., Rovaris M., et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 126:2003;433-437.
58. Gonen O., Catalaa I., Babb J.S., et al. Total brain N-acetylaspartate: a new measure of disease load in multiple sclerosis. Neurology. 54:2000;15-19.
59. Filippi M., Rocca M.A., Colombo B., et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage. 15:2002;559-567.
60. Puri B.K., Counsell S.J., Zaman R., et al. Relative increase in choline in the occipital cortex in chronic fatigue syndrome. Acta Psychiatr Scand. 106:2002;224-226.
61. Chaudhuri A., Condon B.R., Gow J.W., Brennan D., Hadley D.M. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. NeuroReport. 14:2003;225-228.
62. Tomoda A., Mike T., Yamada E., et al. Chronic fatigue syndrome in childhood. Brain Dev. 22:2000;60-64.
63. Chang L., Ernst T., Osborn D., et al. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch Neurol. 55:1998;305-311.
64. Harper P.S. The brain in myotonic dystrophy. Harper P.S. Myotonic dystrophy. 3rd edn:2001;139-165 W B Saunders, London.
65. 2+ channel physiology and disease etiology. Cell Mol Neurobiol. 22:2002;103-120.
66. Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry. 70:2001;4-8.
67. Buckley C., Oger J., Clover L., et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 50:2001;73-78.
68. Jokobi J.M., Killinger D.W., Wolfe B.M., Mahon J.L., Rice C.L. Quadriceps muscle function and fatigue in women with Addison's disease. Muscle Nerve. 24:2001;1040-1049.
69. Merkies I.S.J., Schwartz P.I.M., Samiju J.P.A., van der Mehe F.G.A., van Doorn P.A. Fatigue in immune mediated polyneuropathies. Neurology. 53:1999;1648-1654.
70. Buchwald D., Herrell R., Ashton S., et al. A twin study of chronic fatigue. Psychosom Med. 63:2001;936-943.
71. Smith CUM. Some pathologies. Smith C.U.M. Elements of molecular neurobiology. 3rd edn:2002;507-540 John Wiley, Chichester.
72. Shannon J.R., Flattem N.L., Jordan J., et al. Orthostatic intolerance and tachycardia associated with norepinephrine transporter deficiency. N Engl J Med. 342:2000;541-549.
73. Lowe P.A., Opfer-Gehrking T.L., Textor S.C., et al. Postural tachycardia syndrome (POTS). Neurology. 45:(suppl 5):1995;S19-25.
74. Dinan T.G. Studying brain receptor function: a neuroendocrine approach. Irish J Psychol Med. 10:1993;4-5.
75. Kramer M.S., Cutler N., Feighner J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
76. Griebel G., Simiand J., Serradeil-Le Gal C., et al. Anxiolytic and antidepressant-like effects of thenon-peptide vasopressin V1b receptor antagonist SSR 149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA. 99:2002;6370-6375.
77. Borowsky B., Durkin M.M., Ogozalek K., et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 8:2002;1039.
78. Pellymounter M.A., Joppa M., Ling N., et al. Pharmacological evidence supporting a role for central corticotrophin-releasing factor 2 receptors in behavioural, but not endocrine, responses to environmental stress. J Pharmacol Exp Ther. 302:2002;145-152.
79. Sheenan G.L., Murray N.M.F., Rothwell J.C., et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in treatment of fatigue in multiple sclerosis. Brain. 121:1998;867-875.
80. Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci. 14:1987;273-278.
81. Weinshenker B.G., Penman M., Bass B., et al. A double-blind randomized cross-over trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 42:1992;1468-1471.
82. Trojan D.A., Collet J-P, Shapiro S., et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology. 53:1999;1225-1233.
83. Bruno R.L., Zimmerman J.R., Crenage S.J., et al. Bromocriptine in the treatment of post-polio fatigue: a pilot study with implications for the pathophysiology of fatigue. Am J Phys Med Rehabil. 75:1996;340-347.
84. Stein D.P., Dambrosia J.M., Dalakas M.C. A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with post-polio syndrome. Ann N Y Acad Sci. 753:1995;296-302.
85. Zifko U.A., Rupp M., Schwarz S., Zipko H.T., Maida E.M. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol. 249:2002;983-987.
86. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 72:2002;179-183.
87. Martin S.D., Martin E., Rai S.S., Richardson M.A., Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry. 58:2001;641-648.
88. Tam S.L., Archibald V., Tyreman N., Gordon T. Effect of exercise on stability of chronically enlarged motor units. Muscle Nerve. 25:2002;359-369.
89. Peach P. Effect of treatment and non-compliance on post-polio sequelae. Orthopaedics. 14:1991;1199-1203.
90. McComas A. Early and late losses of motor units after poliomyelitis. Brain. 120:1997;1415-1421.
91. Sutherland G., Andersen M.B. Exercise and multiple sclerosis: physiological, psychological and quality of life issues. J Sports Med Phys Fitness. 41:2001;421-432.
92. American Psychiatric Association. Diagnosis and statistical manual of mental disorders. 4th edn:1994;APA, Washington DC.
93. Pincus J.H., Tucker G.J. Clinical evaluation. Pincus J.H., Tucker G.J. Behavioral neurology. 4th edn:2003;249-267 Oxford University Press, New York.
94. Horrobin D. The madness of Adam and Eve: how schizophrenia shaped humanity. 2002;296 Corgi Books, London.